RB1 is altered in 5.49% of malignant solid tumor patients with RB1 Mutation present in 2.84% of all malignant solid tumor patients [4].

RB1 Mutation is an inclusion criterion in 7 clinical trials for malignant solid tumor, of which 4 are open and 3 are closed. Of the trials that contain RB1 Mutation and malignant solid tumor as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 4 are phase 2 (3 open) [5].

RB1 is altered in 5.75% of prostate carcinoma patients with RB1 Mutation present in 1.72% of all prostate carcinoma patients [4].

RB1 Mutation is an inclusion criterion in 3 clinical trials for prostate carcinoma, of which 3 are open and 0 are closed. Of the trials that contain RB1 Mutation and prostate carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [5].

RB1 is altered in 4.87% of non-small cell lung carcinoma patients with RB1 Mutation present in 2.89% of all non-small cell lung carcinoma patients [4].

RB1 Mutation is an inclusion criterion in 2 clinical trials for non-small cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain RB1 Mutation and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (1 open) [5].

RB1 is altered in 3.3% of colorectal carcinoma patients with RB1 Mutation present in 2.13% of all colorectal carcinoma patients [4].

RB1 Mutation is an inclusion criterion in 2 clinical trials for colorectal carcinoma, of which 0 are open and 2 are closed. Of the trials that contain RB1 Mutation and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (0 open) [5].

RB1 is altered in 3.68% of breast carcinoma patients with RB1 Mutation present in 1.76% of all breast carcinoma patients [4].

RB1 Mutation is an inclusion criterion in 2 clinical trials for breast carcinoma, of which 0 are open and 2 are closed. Of the trials that contain RB1 Mutation and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (0 open) [5].

RB1 is altered in 2.98% of non-hodgkin lymphoma patients with RB1 Mutation present in 1.23% of all non-hodgkin lymphoma patients [4].

RB1 Mutation is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain RB1 Mutation and non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [5].

RB1 is altered in 61.45% of retinoblastoma patients with RB1 Mutation present in 31.33% of all retinoblastoma patients [4].

RB1 Mutation is an inclusion criterion in 1 clinical trial for retinoblastoma, of which 1 is open and 0 are closed. Of the trial that contains RB1 Mutation and retinoblastoma as inclusion criteria, 1 is no phase specified (1 open) [5].

RB1 is altered in 16.16% of bladder carcinoma patients with RB1 Mutation present in 10.01% of all bladder carcinoma patients [4].

RB1 Mutation is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RB1 Mutation and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

RB1 is altered in 14.62% of urothelial carcinoma patients with RB1 Mutation present in 9.3% of all urothelial carcinoma patients [4].

RB1 Mutation is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RB1 Mutation and urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

RB1 is altered in 11.32% of glioblastoma patients with RB1 Mutation present in 5.2% of all glioblastoma patients [4].

RB1 Mutation is an inclusion criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains RB1 Mutation and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [5].

RB1 is altered in 4.48% of cervical carcinoma patients with RB1 Mutation present in 2.99% of all cervical carcinoma patients [4].

RB1 Mutation is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RB1 Mutation and cervical carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

RB1 is altered in 9.94% of soft tissue sarcoma patients with RB1 Mutation present in 2.83% of all soft tissue sarcoma patients [4].

RB1 Mutation is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains RB1 Mutation and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

RB1 is altered in 10.1% of sarcoma patients with RB1 Mutation present in 2.69% of all sarcoma patients [4].

RB1 Mutation is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains RB1 Mutation and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [5].

RB1 is altered in 3.45% of melanoma patients with RB1 Mutation present in 2.55% of all melanoma patients [4].

RB1 Mutation is an inclusion criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains RB1 Mutation and melanoma as inclusion criteria, 1 is phase 1 (0 open) [5].

RB1 is altered in 4.03% of head and neck carcinoma patients with RB1 Mutation present in 2.5% of all head and neck carcinoma patients [4].

RB1 Mutation is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RB1 Mutation and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

RB1 is altered in 4.08% of esophageal carcinoma patients with RB1 Mutation present in 2.09% of all esophageal carcinoma patients [4].

RB1 Mutation is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RB1 Mutation and esophageal carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

RB1 is altered in 3.06% of gastric carcinoma patients with RB1 Mutation present in 1.86% of all gastric carcinoma patients [4].

RB1 Mutation is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RB1 Mutation and gastric carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

RB1 is altered in 5.19% of prostate adenocarcinoma patients with RB1 Mutation present in 1.65% of all prostate adenocarcinoma patients [4].

RB1 Mutation is an inclusion criterion in 1 clinical trial for prostate adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RB1 Mutation and prostate adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

RB1 is altered in 4.03% of ovarian carcinoma patients with RB1 Mutation present in 1.57% of all ovarian carcinoma patients [4].

RB1 Mutation is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RB1 Mutation and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

RB1 is altered in 4.45% of high grade ovarian serous adenocarcinoma patients with RB1 Mutation present in 1.54% of all high grade ovarian serous adenocarcinoma patients [4].

RB1 Mutation is an inclusion criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains RB1 Mutation and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

RB1 is altered in 1.99% of anal carcinoma patients with RB1 Mutation present in 1.49% of all anal carcinoma patients [4].

RB1 Mutation is an inclusion criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RB1 Mutation and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

RB1 is altered in 2.62% of pancreatic carcinoma patients with RB1 Mutation present in 1.44% of all pancreatic carcinoma patients [4].

RB1 Mutation is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RB1 Mutation and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

RB1 is altered in 3.22% of anaplastic astrocytoma patients with RB1 Mutation present in 1.29% of all anaplastic astrocytoma patients [4].

RB1 Mutation is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains RB1 Mutation and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) [5].

RB1 is altered in 2.98% of lymphoma patients with RB1 Mutation present in 1.29% of all lymphoma patients [4].

RB1 Mutation is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains RB1 Mutation and lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].

RB1 is altered in 0.51% of clear cell renal cell carcinoma patients with RB1 Mutation present in 0.38% of all clear cell renal cell carcinoma patients [4].

RB1 Mutation is an inclusion criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RB1 Mutation and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

RB1 is altered in 0.75% of histiocytic and dendritic cell neoplasm patients with RB1 Mutation present in 0.37% of all histiocytic and dendritic cell neoplasm patients [4].

RB1 Mutation is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RB1 Mutation and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

RB1 is altered in 0.32% of acute myeloid leukemia patients with RB1 Mutation present in 0.26% of all acute myeloid leukemia patients [4].

RB1 Mutation is an inclusion criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains RB1 Mutation and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

RB1 is altered in 0.35% of myeloid neoplasm patients with RB1 Mutation present in 0.26% of all myeloid neoplasm patients [4].

RB1 Mutation is an inclusion criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RB1 Mutation and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

RB1 is altered in 0.5% of germ cell tumor patients with RB1 Mutation present in 0.12% of all germ cell tumor patients [4].

RB1 Mutation is an inclusion criterion in 1 clinical trial for germ cell tumor, of which 0 are open and 1 is closed. Of the trial that contains RB1 Mutation and germ cell tumor as inclusion criteria, 1 is phase 2 (0 open) [5].

RB1 Mutation is an inclusion criterion in 1 clinical trial for childhood brain stem glioma, of which 1 is open and 0 are closed. Of the trial that contains RB1 Mutation and childhood brain stem glioma as inclusion criteria, 1 is phase 1 (1 open) [5].

RB1 Mutation is an inclusion criterion in 1 clinical trial for diffuse intrinsic pontine glioma, of which 1 is open and 0 are closed. Of the trial that contains RB1 Mutation and diffuse intrinsic pontine glioma as inclusion criteria, 1 is phase 1 (1 open) [5].

RB1 Mutation is an inclusion criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains RB1 Mutation and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (1 open) [5].

RB1 Mutation is an inclusion criterion in 1 clinical trial for penile carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RB1 Mutation and penile carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

RB1 is altered in 14.29% of vaginal carcinoma patients [4].

RB1 Mutation is an inclusion criterion in 1 clinical trial for vaginal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RB1 Mutation and vaginal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

RB1 Mutation is an inclusion criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RB1 Mutation and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].